Transient muscle paralysis engendered by a single injection of botulinum toxin A (BTxA) rapidly 27 induces profound focal bone resorption within the medullary cavity of adjacent bones. While initially 28 conceived as a model of mechanical disuse, osteoclastic resorption in this model is disproportionately severe 29 compared to the modest gait defect that is created. Preliminary studies of bone marrow following muscle 30 paralysis suggested acute upregulation of inflammatory cytokines, including TNF and IL-1. We therefore 31 hypothesized that BTxA-induced muscle paralysis would rapidly alter the inflammatory microenvironment and 32 the osteoclastic potential of bone marrow. We tested this hypothesis by defining the time course of 33 inflammatory cell infiltration, osteoinflammatory cytokine expression, and alteration in osteoclastogenic 34 potential in the tibia bone marrow following transient muscle paralysis of the calf muscles. Our findings 35 identified inflammatory cell infiltration within 24 hours of muscle paralysis. By 72 hours, osteoclast fusion and 36 pro-osteoclastic inflammatory gene expression were upregulated in tibia bone marrow. These alterations 37 coincided with bone marrow becoming permissive to the formation of osteoclasts of greater size and greater 38 nuclei numbers. Taken together, our data are consistent with the thesis that transient calf muscle paralysis 39 induces acute inflammation within the marrow of the adjacent tibia and that these alterations are temporally 40 consistent with a role in mediating muscle paralysis-induced bone resorption. 41 42 Introduction 43
Introduction 43
Transient muscle paralysis induced by a single injection of botulinum toxin A (BTxA) rapidly induces 44 focal and profound bone resorption within the medullary cavity of adjacent bones. While initially conceived as 45 a model of bone loss due to reduced gait-induced loading, osteoclastic resorption in this model is 46 disproportionately severe compared to the modest gait defect that is created (19, 32, 49) . Instead, the severe 47 bone loss following BTxA-induced muscle paralysis is comparable in rapidity and magnitude to that induced by 48 sciatic neurectomy and spinal cord injury (31, 34) . Subsequent studies demonstrated that acute trabecular bone 49 loss following muscle paralysis arises via profound RANKL mediated osteoclastogenesis, but the initial 50 signaling cascade responsible for the rapid activation of this bone catabolic pathway is not known (2) . 51
Preliminary studies to identify candidate signaling pathways responsible for activating RANKL-52 mediated osteoclastogenesis indicated that the inflammatory cytokines TNFα and IL-1 were upregulated prior to 53 the onset of bone resorption and to altered bone marrow gene expression previously observed at 7 and 14 d 54 post-paralysis (33, 53). As these cytokines have been shown to regulate osteoclast activity (1, 12, 27, 56) , we 55 speculated that inflammatory alterations within the marrow in response to muscle paralysis create a focal 56 microenvironment that is permissive to osteoclastogenesis. 57
The linkage between inflammation, immune function, and bone catabolism is strongly supported by the 58 literature. Predisposition to bone loss and osteoporotic fracture is observed in a number of chronic 59 inflammatory diseases with immune components such as rheumatoid arthritis, inflammatory bowel disease, 60 chronic obstructive pulmonary disease, and multiple sclerosis (8, 15, 17, 41) . Inflammatory pathways have also 61 been implicated in post-menopausal bone loss (40). When focal inflammatory disorders occur adjacent to bone 62 surfaces (e.g., periodontitis or adjuvant arthritis), bone resorption is especially destructive (3, 29) . One 63 mechanism for this resorption is that RANKL can be highly expressed on activated CD4+ T cells and other 64 inflammatory regulating cells (24, 25, 48) , leading to enhanced osteoclast formation/recruitment and bone 65 destruction. As well, inflammatory cytokines such as TNFα, IL-1 and IL-6 have been found to promote 66 osteoclastogenesis (3, 20) and are implicated in post-menopausal bone loss (40). Lastly, both genetic andpharmacologic inhibition of the immune response through T cell depletion and/or anti-inflammatory treatment 68 reduces bone loss in models of ovariectomy and adjuvant arthritis (9, 40, 42) . 69
In addition to clear evidence of immune system involvement in chronic inflammatory bone loss, the 70 rapidity and magnitude of bone resorption induced by muscle paralysis implies that immune-inflammatory 71 pathways may play a critical role in paralysis-induced bone loss. In this context, an advantage of exploring this 72 phenomenon in the BTxA bone loss model is the brief, contained period of de novo osteoclast activity (6 to 13 73 days; (5)) induced by muscle paralysis. We therefore hypothesized that BTxA-induced muscle paralysis would 74 rapidly alter the inflammatory microenvironment and the osteoclastic potential of bone marrow. We tested this 75 hypothesis by defining the time course of inflammatory cell infiltration, osteoinflammatory cytokine expression, 76
and alteration in osteoclastogenic potential in the tibia bone marrow following transient muscle paralysis of the 77 adjacent calf muscle group. 78
79

Methods 80
This study was comprised of three complementary experiments. All mice were 16-wk-old female 81
C57Bl/6 obtained from Jackson Laboratories. Each experiment utilized a single injection of botulinum toxin A 82 (BTxA; 2U/100 g body weight; Allergan, Irvine, CA, USA) into the right calf muscle group to induce transient 83 muscle paralysis on day 0 (39). Mice receiving BTxA treatment were allowed free cage activity for the 84 remainder of each experiment. Calf paralysis was confirmed 24 hours post-injection by visual examination of 85 reduced toe extension and ankle plantarflexion in the affected limb. We chose to use age matched naïve mice as 86 controls in our studies for two primary reasons. First, while we have observed minimal alterations in RANKL 87 protein levels, osteoclast numbers and bone volume alterations in control limbs following BTxA induced 88 muscle paralysis (2, 50), we had no data confirming the absence of inflammatory gene expression alterations in 89 contralateral limbs. Second, we had previously used naïve control mice to define the onset of osteoclastic 90 resorption following transient muscle paralysis (4, 5) . All experiments were performed in accordance with 91 protocols approved by the Institutional Animal Care and Use Committee, University of Washington. were washed twice and resuspended in FACS buffer for flow cytometry analysis. Marrow from naïve mice 01 (n=5) was identically collected and processed as the baseline control. Marrow cell populations were stained for 02 T cell surface markers (TCRβ, CD4 and CD8 antibodies: Biolegend) . Individual sample data were acquired on 03 an LSRII flow cytometer (BD Biosciences) and analyzed using FlowJo software (Treestar). Prior to analysis, 04 one mouse from the BTxA group was removed due to a failed physical examination for muscle paralysis. 05
06
Quantitative RT-PCR of Osteoinflammatory and Osteoclast Fusion Genes 07
Mice in this study were sacrificed on day 1, 3 or 7 post BTxA injection (n=6/grp). Whole marrow was 08 flushed from the right tibia with RPMI. For quantitative RT-PCR, total RNA was extracted using the RNeasy 09
Mini Kit (Qiagen) according to manufacturer's protocol and cDNA was synthesized using Super Script III 10 reverse transcriptase (Invitrogen/Life Technologies). Control marrow from naïve mice was prepared identically 11 (n=6). We identified a candidate panel of inflammatory and osteoclastogenic genes from the literature and 12 based on our preliminary data (TNF, CD9, CD44, CD47, CD81, IL1a, IL1b, IL4, IL11, DC-STAMP, OC-13 STAMP). We analyzed gene expression with quantitative real-time PCR using SYBR green and the Applied 14
Biosystems 7900 HT sequence detection system. Gene expression levels were quantified using the 2-(2AACT) 15 method relative to the inflammatory specific housekeeping gene HPRT (45). Primers used for this analysis are 16 shown in Table 1 . 17
18
Primary Osteoclast Culture
Tissue culture medium and supplements were purchased from Invitrogen (Life Technologies). Media 20 were supplemented with heat-inactivated FBS (HyClone, Thermo Scientific). Marrow was collected from 21 mouse tibiae at 1, 3 and 7 days post BTxA injection (n=2/gp). Marrow was flushed in culture medium (α-MEM 22 with 10% FBS) and red blood cells were lysed as previously described above. Cells were seeded in duplicate at 23
x 10
4 /cm 2 in chamber well slides (Thermo Scientific Inc.), supplemented with 50 ng/ml M-CSF (Peprotech) 24 and 10 ng/ml RANKL (Biolegend) and incubated at 37°C and 5% CO 2 . Cell media were refreshed on day 3 of 25 culture and cells were fixed and stained for tartrate resistant acid phosphatase (TRAP) on day 8 of culture using 26 the Leukocyte (TRAP) kit and protocol (Sigma-Aldrich). The experiment was replicated (total combined group 27 size of n=4/grp), with data normalized within each experiment to identically treated marrow from treatment-28 naïve mice (n=2/exp). For each group, normal osteoclasts (i.e., TRAP-positive cells w/ 3+ nuclei) and giant 29 osteoclasts (i.e., a subset of normal osteoclasts w/ 20+ nuclei) were quantified on a per well basis using bright 30 field microscopy (Olympus BH2 microscope, 10X and 40X magnification). The cutoff for a giant osteoclast 31 (20+ nuclei) was based on previous studies (22, 51) in order to distinguish an increase in cell size between 32 experimental groups. Once this difference was identified, a secondary analysis was performed to quantify the 33 cell size distribution within these identified samples to confirm that our original analysis was robust to our 34 choice of what was considered a giant osteoclast. For this, we assessed osteoclast area in naïve and 3 days post-35
BTxA cultures via automated calculation of osteoclast TRAP+ cell area in two 10 mm 2 subsamples of the 36 culture area (composite of eighty 20x light microscopy images, Ziess) using custom ImageJ software (FIJI). 37
Specifically, the software identified individual cell perimeters through image thresholding, binarized the images 38 and filled in the cell area for individual cell area calculations. The average size of a 3-nuclei osteoclast was 39 quantified by imaging a series of 3-nuclei TRAP+ cells (n=20 cells across all groups). 40
41
Statistical Analysis 42
Due to non-homogeneity of variance, flow cytometry data were analyzed using Kruskal-Wallis rank sum 43 tests with Dunn's post-hoc analysis for pair-wise comparisons. Differential gene regulation in the quantitative 44
RT-PCR study was determined using planned comparison one-way MANOVAs (i.e., gene expression on alldays compared to naïve mice) with Dunnett's two-way post-hoc for multiple comparisons to controls (i.e., 46 naïve). Multiple one-way ANOVAs with Tukey post-hoc analysis were used to determine significantdifferences in the primary osteoclast culture. To compare osteoclast size in cultures, a Kolmogorov-Smirnov 48 (KS) test was first used to compare the distribution in cell areas. Next, normalized population distributions (i.e., 49 percent of cell population at a given area) were determined and fit with separate power law curves using 50 maximum likelihood estimation (MLE) and likelihood ratio testing (LRT) as described previously (46). Finally, 51
we assessed whether the data sets could be fit by a single power law model via MLE and LRT. Statistical 52 significance was determined to be p<0.05. 53 54
Results
55
CD4+ T Cells Are Acutely Upregulated Following Muscle Paralysis 56
Flow cytometry revealed rapid transient alterations in tibia marrow cell populations in the proximal tibia 57 metaphysis following muscle paralysis (Fig. 1) . The percentage of CD4+ T cells (mean ± s.e.) within the bone 58 marrow was elevated 25% within 24 hours of BTxA injection (1.47 ± 0.07%) vs naïve (1.14 ± 0.10%, p<0.04; 59 Fig. 1B ), but returned to baseline levels with 48 hours after BTxA injection (1.14 ± 0.07%, p=0.75 vs naive; 60 Fig. 1B ). CD8+ populations were not significantly altered at any timepoint (2.36 ± 0.21% vs 2.32 ± 0.20% vs 61 2.52 ± 0.35 in day 1, day 2, and naïve, respectively, p>0.9; Fig. 1C) . Thus, the ratio of CD4+/CD8+ T cells 62 within the marrow was increased 34% on day 1 (0.63 ± 0.04) vs naïve (0.47 ± 0.04, , p<0.03; Fig. 1D ), but not 63 on day 2 (0.49 ± 0.01, p=0.82 vs naive; Fig. 1C) . The overall T cell population size in naïve marrow (40.17 ± 64 1.78%) was not significantly altered at 24 hours (42.40 ± 2.91%, p=0.36 vs naive; Fig. 1E ) or 48 hours (33.20 ± 65 2.24%, p=0.10 vs naive; Fig. 1E) . 66
67
Osteoinflammatory Genes Are Rapidly Altered Following Muscle Paralysis 68
Temporal gene expression patterns within the tibia marrow following muscle paralysis were consistent 69 with transient inflammatory signaling. While none of the panel of nine genes was significantly altered at 1 day 70 following muscle paralysis (vs naïve controls), three genes showed statistically significant regulation by day 3. 71
Two genes were upregulated (TNF: 299%, IL-4: 243%; each p<0.02, Table 2), while one was downregulated 72 (CD47: -88%; p<0.03, Table 2 ). Only IL-4 was significantly upregulated on day 7 (250%, p<0.02, Table 2 ). 73
Additionally, three other genes (CD9, IL-1a and IL-1b; Table 2 ) were detectable in naïve and day 1 samples, 74 but were undetectable on days 3 and 7. IL-6 gene expression was also assayed but the levels were undetectable 75 in most samples and thus not reported. 76
77
The Osteoclastic Potential of Bone Marrow Is Altered by Muscle Paralysis 78
The culture conditions were permissive to the formation of osteoclasts with a small subset of giant 79 osteoclasts (> 20 nuclei; Fig 2) . Marrow from naïve mice generated 96.8 ± 26.7 (mean ± s.e.) normal 80 osteoclasts/well, including 2.5 ± 1.0 giant osteoclasts/well. Transient muscle paralysis did not significantly alter 81 the number of normal osteoclasts formed in marrow culture at any time point (Fig. 3A) . However, the capacity 82 to form giant osteoclasts was acutely upregulated 3 days following muscle paralysis, and was not significantly 83 different from naïve mice by day 7. Marrow harvested 3 days after BTxA injection produced 268% more giant 84 osteoclasts than naïve control marrow (p=0.008) and 352% more giant osteoclasts than day 1 marrow (p=0.003; 85
Fig. 3B). Secondary analyses indicated that this observation was robust to the number of nuclei chosen to 86 represent a giant osteoclast. A KS Test indicated that the distribution of osteoclast size arising from day 3 87
BTxA marrow was significantly different than that of naïve bone marrow (p<0.001). Additionally, we observed 88 that two separate power law models (a*x b ) were required to describe the in vivo data (p=0.87, formulas in Fig  89   4 ). Given that the overall osteoclast numbers were not different in naïve and day 3 BTxA cultures (see above), 90 this analysis indicates that the percentage of cells (and thus total cell number) in the day 3 BTxA culture were 91 higher than in the naïve cultures regardless of the threshold chosen to classify a giant osteoclast. 92
93
Osteoclast Fusion Genes Are Upregulated 3 Days Following Muscle Paralysis 94
The elevated osteoclast size and number of nuclei generated by marrow following muscle paralysis 95 might be explained by enhanced cell fusion. We therefore reassessed cDNA from the gene expression 96 experiment and quantified alterations in the osteoclast fusion genes (DC-STAMP and OC-STAMP). Both DC-97 STAMP (243% increase) and OC-STAMP (218% increase) were significantly upregulated in bone marrow 98 removed 3 days post-paralysis as compared to naïve bone marrow (both p< 0.02, Fig 5) . Consistent with the in 99 vitro experiments, osteoclast fusion gene expression was not significantly altered on day 1 or day 7 following 00 muscle paralysis compared to naïve samples. 01
02
Discussion 03
We used flow cytometry, quantitative RT-PCR, and primary osteoclast culture to explore the presence of 04 inflammatory signaling within bone marrow following calf paralysis. We observed inflammatory cell 05 infiltration within 24 hours and pro-inflammatory gene expression within 72 hours of muscle paralysis. 06 Surprisingly, alterations in the osteoclastic potential of bone marrow extracted following muscle paralysis were 07 not associated with increased numbers of osteoclasts, but instead manifested as an increase in osteoclast size 08 and number of nuclei per osteoclast. The observation of enhanced numbers of giant osteoclasts was supported 09 by simultaneous upregulation of the osteoclast fusion genes DC-and OC-STAMP. In combination, these data 10 are consistent with muscle paralysis acutely precipitating a localized inflammatory response within bone 11 marrow that is permissive to generating osteoclasts of greater size and nuclei number. 12
These observations must be considered in the context of the limitations of our approach. The impetus 13 for this study was to assess our thesis that inflammatory signaling within bone marrow precedes or is coincident 14 with the onset of bone resorption induced by muscle paralysis. To that end, we quantified inflammatory cell 15 influx (FACS) and altered osteoinflammatory signaling (RT-PCR) within bone marrow. While recognizing that 16 these outcomes are indirect and do not define a causal relationship between bone marrow inflammation and 17 subsequent bone resorption, we believe this limitation is mitigated, in part, by the cadence of events underlying 18 bone resorption following muscle paralysis. Specifically, we observed alterations in inflammatory cell 19 populations (day 1) upstream of alterations in osteoinflammatory gene expression (day 3). The timing in which 20 marrow became permissive to formation of giant osteoclasts (day 3), coupled with the time needed to form 21 functioning osteoclasts from precursor populations (≈ 3-5 days (13, 47) ) is congruent with the onset ofdiaphyseal endocortical resorption following paralysis (which almost entirely occurs between days 6 and 13 23
post-paralysis) (5). 24
To further support our gene expression data, we performed a follow-on ELISA-based study to quantify 25 protein level alterations in TNF and IL4 (as both genes showed significant upregulation following muscle 26 paralysis). Utilizing the same time points as the gene expression experiment, we did not observe elevated 27 expression in either protein following muscle paralysis. There are many potential explanations for the lack of 28 direct correlation between mRNA and protein levels, and the inflammatory literature illustrates this challenge 29 even in a simple cell culture environment (e.g., (44)). One clear challenge in our system is that the temporal 30 dynamics of protein expression and stability (e.g., half-life on the scale of minutes in an experiment of many 31 days) is likely to be exceedingly non-linear. Though we believe the cumulated data across our studies suggest 32 otherwise, it is possible that the inflammatory genes upregulation does not manifest in alteration in protein level 33 expression. Regardless, these data support the need to further clarify the role of inflammatory mediation and 34 suggest that either transgenic (6, 40) or pharmaceutical (9, 42) strategies would most effectively explore a 35 mechanistic relation between inflammation and muscle paralysis-induced bone loss. 36
Using a primary culture system to explore whether bone marrow had altered osteoclastic potential 37 following transient muscle paralysis, we observed greater numbers of giant osteoclasts (>20 nuclei). This 38 finding ostensibly contradict our previous in vivo observation of increased osteoclast numbers in the proximal 39 tibia following BTxA-induced paralysis of the calf (2). However, as histologic quantification of osteoclast 40 numbers in adjacent cross-sections relies upon an assumption of equivalent cell size, a significant increase in 41 osteoclast size (as observed in vitro) would likely manifest as an increased osteoclast number in stereological 42 assessments. Additionally, we did not determine the resorptive potential of the giant osteoclasts observed in 43 cell culture. The literature suggests that osteoclast size does not always correlate with increased bone 44 resorption. For example, giant osteoclasts observed following long-term bisphosphonate therapy are generally 45 not thought to resorb bone at all, but rather are an artifact caused by prolonged apoptosis (22, 51). In contrast, 46 however, giant osteoclasts associated with inflammatory pathologies such as Paget's are generally thought to be 47 capable of resorbing large volumes of bone mineral (16, 21, 29, 38 ). If so, it is reasonable to speculate that arelatively few giant osteoclasts could account for a sizeable proportion of bone resorption observed following 49 muscle paralysis. As confirmation of the in vivo presence of giant osteoclasts via histology may prove 50 technically challenging, given our observations of enhanced cell fusion, it is possible that pharmaceutical 51 strategies to transiently inhibit cell fusion could be implemented to explore this question in vivo (18) . 52 Despite these limitations, our results are consistent with the upregulation of inflammatory cells and 53 inflammatory genes prior to the initiation of bone resorption, and our in vivo RT-PCR data are also consistent 54 with this altered marrow environment facilitating the formation of giant osteoclasts observed in vitro. 55
Following muscle paralysis, several genes implicated in osteoclast fusion and giant osteoclast formation were 56 upregulated, including the essential protein for osteoclast fusion, 43, 54) , and a second 57 osteoclast fusion related protein, OC-STAMP (36). Inhibition studies have indicated that these genes are 58 essential for normal osteoclast activity, while overexpression studies having resulted in elevated osteoclast 59 formation/bone resorption (11, 28, 52, 55) . IL-4 has been shown to promote the formation of multinucleated 60 giant cells from macrophage precursors through the overexpression of E-cadherin (37). Other recent reports 61 identified that upregulation of TNF in the absence of CD44 results in the generation of highly resorbing giant 62 osteoclast (21). While we did not detect a statistical decrease in CD44 gene expression on day 3 (p=0.10), the 63 87% decrease in comparison to naïve bone marrow and elevated TNF in our data are also consistent with this 64
thesis. 65
Ultimately, understanding how muscle paralysis of the calf induces inflammatory alterations in tibia 66 bone marrow may reveal unexpected targets to mitigate the catabolic effects of neuromuscular dysfunction, 67 regardless of initiating pathology. One possible explanation is that muscle paralysis induces neurogenic 68 inflammation, which is characterized by the local release of inflammatory mediators in response to trauma or 69 noxious stimuli (10, 23, 30) . Classically, antidromic depolarization causes sensory neurons to rapidly release 70 neuropeptides (primarily SP and CGRP; (10, 14) ) that act on a variety of cell populations to rapidly orchestrate 71 a focal inflammatory response (7). While direct evidence of neuropeptide release following muscle paralysis 72
has not yet been reported, even brief periods of weightlessness have been associated with afferent sensory nerve 73 depolarization (26).
Taken together, our data suggest that transient calf muscle paralysis induces acute inflammation within 75 the marrow of the adjacent tibia that is temporally consistent with an active role in mediating bone resorption 76 induced by this neuromuscular dysfunction. Our data additionally suggest that the inflammatory cascade 77 swiftly triggered by transient muscle paralysis predisposes bone marrow to the formation of giant osteoclasts, 78 which may account for the rapid and severe destruction of trabecular bone observed in this model. The 79 identification of an acute inflammatory cascade in bone marrow leading to the formation of giant osteoclasts has 80 potential to reveal novel therapeutic strategies for mitigating paralysis-induced bone loss following 81 neuromuscular trauma. 82 tibia of naïve mice and from mice that had received an IM injection of BTxA injection in the right calf 1, 3 and 02 7 days previously. Cells were cultured for 8 days, and stained for TRAP. Normal osteoclast (TRAP + w/3+ 03 nuclei) and giant osteoclast (a subset of normal osteoclasts w/20+ nuclei) were quantified in each group on a per 04 well basis using bright field microscopy (10 to 40x magnification). Fold changes of osteoclasts (A) and giant 05 osteoclasts (B) are shown at day 1, 3 and 7 post injection normalized to the naïve controls. Values represent 06 mean + SE (n=4 per group), **p<0.01 vs naïve and day 1. 07
Figure 4: Size of osteoclasts generated from marrow harvested 3 days after muscle paralysis was 09 consistently larger than that of Naïve marrow cultures. An automated quantification of osteoclast area was 10 performed on two subsamples of the naïve and day 3 cultures (10 mm 2 per subsample using a composite of 11 eighty light microscopy 20x images) using custom software as described in the Materials and Methods. A 
